Exicure Partners with Adbiotech for Burixafor Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy XCUR?
Source: Newsfilter
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea's Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, marking a strategic expansion in the biotechnology sector.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, establishing a foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, indicating its potential applicability in treatment.
- Research and Development Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, ensuring the smooth progression of the research.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials based on further agreements, demonstrating a strong commitment to future clinical development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XCUR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XCUR
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has signed a co-development agreement with Korean biotech firm Adbiotech to utilize Burixafor for combination therapies targeting hematological diseases, marking a strategic expansion in the biopharmaceutical sector.
- Drug Development Background: Burixafor (GPC-100) is an investigational drug that has successfully completed a Phase 2 clinical trial for multiple myeloma and is currently being explored for various hematological indications, indicating its broad clinical potential.
- Defined Research Focus: Under the agreement, Adbiotech will conduct in vitro studies for preclinical validation, while Exicure will lead the clinical and regulatory strategy, ensuring a smooth development process for the drug.
- IND Submission Goal: The two companies are collaborating to advance research on Burixafor with the aim of submitting an investigational new drug (IND) application, further propelling the drug's path to market.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea's Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, marking a strategic expansion in the biotechnology sector.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, establishing a foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, indicating its potential applicability in treatment.
- Research and Development Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, ensuring the smooth progression of the research.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials based on further agreements, demonstrating a strong commitment to future clinical development.
See More
Exicure Partners with Adbiotech for Combination Therapy Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea-based Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, indicating a strategic expansion into various indications.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a solid foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, potentially supporting future clinical development.
- Research and Funding Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, with plans to secure funding for future clinical development.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials, reflecting a strong commitment to exploring Burixafor's potential in combination therapies.
See More
EXICURE AND ADBIOTECH ENTER CO-DEVELOPMENT PARTNERSHIP FOR BURIXAFOR (GPC-100)
Announcement of Co-Development Agreement: Exicure has announced a co-development agreement with ADBIOTECH for the development of a new therapeutic product, GP-C-100.
Focus on Burixafor: The collaboration centers around Burixafor, which is aimed at enhancing treatment options in specific medical conditions.
See More
Exicure Reports Liquidity Crisis with FY GAAP EPS of -$0.79
- Poor Financial Performance: Exicure's FY report reveals a GAAP EPS of -$0.79, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Liquidity Decline: As of December 31, 2025, Exicure's cash and cash equivalents dropped to $3.7 million from $12.5 million a year earlier, highlighting urgent concerns regarding the company's financial management and liquidity position.
- Insufficient Operating Funds: The company warns that its current liquidity may not be sufficient to fund operations for the next 12 months, necessitating additional financing to maintain daily operations and explore strategic alternatives, which could affect its long-term growth strategy.
- Urgent Financing Needs: Exicure states that it must seek additional financing to support ongoing operations and any identified strategic alternatives, a requirement that may lead to shareholder dilution and increased financing costs, further exacerbating market concerns about its financial health.
See More
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has signed a co-development agreement with Korean biotech firm Adbiotech to utilize Burixafor for combination therapies targeting hematological diseases, marking a strategic expansion in the biopharmaceutical sector.
- Drug Development Background: Burixafor (GPC-100) is an investigational drug that has successfully completed a Phase 2 clinical trial for multiple myeloma and is currently being explored for various hematological indications, indicating its broad clinical potential.
- Defined Research Focus: Under the agreement, Adbiotech will conduct in vitro studies for preclinical validation, while Exicure will lead the clinical and regulatory strategy, ensuring a smooth development process for the drug.
- IND Submission Goal: The two companies are collaborating to advance research on Burixafor with the aim of submitting an investigational new drug (IND) application, further propelling the drug's path to market.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea's Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, marking a strategic expansion in the biotechnology sector.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, establishing a foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, indicating its potential applicability in treatment.
- Research and Development Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, ensuring the smooth progression of the research.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials based on further agreements, demonstrating a strong commitment to future clinical development.
See More
Exicure Partners with Adbiotech for Combination Therapy Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea-based Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, indicating a strategic expansion into various indications.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a solid foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, potentially supporting future clinical development.
- Research and Funding Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, with plans to secure funding for future clinical development.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials, reflecting a strong commitment to exploring Burixafor's potential in combination therapies.
See More
EXICURE AND ADBIOTECH ENTER CO-DEVELOPMENT PARTNERSHIP FOR BURIXAFOR (GPC-100)
Announcement of Co-Development Agreement: Exicure has announced a co-development agreement with ADBIOTECH for the development of a new therapeutic product, GP-C-100.
Focus on Burixafor: The collaboration centers around Burixafor, which is aimed at enhancing treatment options in specific medical conditions.
See More
Exicure Reports Liquidity Crisis with FY GAAP EPS of -$0.79
- Poor Financial Performance: Exicure's FY report reveals a GAAP EPS of -$0.79, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Liquidity Decline: As of December 31, 2025, Exicure's cash and cash equivalents dropped to $3.7 million from $12.5 million a year earlier, highlighting urgent concerns regarding the company's financial management and liquidity position.
- Insufficient Operating Funds: The company warns that its current liquidity may not be sufficient to fund operations for the next 12 months, necessitating additional financing to maintain daily operations and explore strategic alternatives, which could affect its long-term growth strategy.
- Urgent Financing Needs: Exicure states that it must seek additional financing to support ongoing operations and any identified strategic alternatives, a requirement that may lead to shareholder dilution and increased financing costs, further exacerbating market concerns about its financial health.
See More
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
See More
